1
|
Abstract
Since its discovery in 1988, B-type natriuretic peptide (BNP) has been recognized as a powerful cardiovascular biomarker for a number of disease states, specifically heart failure. Concurrent with such a discovery, much effort has been allocated to the precise monitoring of physiological BNP levels. Thus, it can be used to guide the therapy of heart failure and determine the patient's stage of disease. Thus, we discuss in this article BNP as a potent biomarker. Subsequently, we will review the progress of biosensing devices as they could be applied to monitor BNP levels as assays, benchtop biosensors and implantable biosensors. The analytical characteristics of commercially available BNP assays are presented. Still emerging as a field, we define four obstacles that present opportunity for the future development of implantable biosensor: foreign body response, sensor renewability, sensitivity and selectivity.
Collapse
|
2
|
Tuo J, Sun H, Shen D, Wang H, Wang Y. Optimization of insulin pump therapy based on high order run-to-run control scheme. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2015; 120:123-134. [PMID: 25981797 DOI: 10.1016/j.cmpb.2015.04.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Revised: 04/08/2015] [Accepted: 04/20/2015] [Indexed: 06/04/2023]
Abstract
BACKGROUND AND OBJECTIVES Continuous subcutaneous insulin infusion (CSII) pump is widely considered a convenience and promising way for type 1 diabetes mellitus (T1DM) subjects, who need exogenous insulin infusion. In the standard insulin pump therapy, there are two modes for insulin infusion: basal and bolus insulin. The basal-bolus therapy should be individualized and optimized in order to keep one subject's blood glucose (BG) level within the normal range; however, the optimization procedure is troublesome and it perturb the patients a lot. Therefore, an automatic adjustment method is needed to reduce the burden of the patients, and run-to-run (R2R) control algorithm can be used to handle this significant task. METHODS In this study, two kinds of high order R2R control methods are presented to adjust the basal and bolus insulin simultaneously. For clarity, a second order R2R control algorithm is first derived and studied. Furthermore, considering the differences between weekdays and weekends, a seventh order R2R control algorithm is also proposed and tested. RESULTS In order to simulate real situation, the proposed method has been tested with uncertainties on measurement noise, drifts, meal size, meal time and snack. The proposed method can converge even when there are ±60 min random variations in meal timing or ±50% random variations in meal size. CONCLUSIONS According to the robustness analysis, one can see that the proposed high order R2R has excellent robustness and could be a promising candidate to optimize insulin pump therapy.
Collapse
Affiliation(s)
- Jianyong Tuo
- College of Information Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China
| | - Huiling Sun
- College of Information Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China
| | - Dong Shen
- College of Information Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China
| | - Hui Wang
- College of Information Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China
| | - Youqing Wang
- College of Information Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China.
| |
Collapse
|
3
|
Devadhasan JP, Kim S, Choi CS. CMOS image sensors as an efficient platform for glucose monitoring. Analyst 2014; 138:5679-84. [PMID: 23900281 DOI: 10.1039/c3an00805c] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Complementary metal oxide semiconductor (CMOS) image sensors have been used previously in the analysis of biological samples. In the present study, a CMOS image sensor was used to monitor the concentration of oxidized mouse plasma glucose (86-322 mg dL(-1)) based on photon count variation. Measurement of the concentration of oxidized glucose was dependent on changes in color intensity; color intensity increased with increasing glucose concentration. The high color density of glucose highly prevented photons from passing through the polydimethylsiloxane (PDMS) chip, which suggests that the photon count was altered by color intensity. Photons were detected by a photodiode in the CMOS image sensor and converted to digital numbers by an analog to digital converter (ADC). Additionally, UV-spectral analysis and time-dependent photon analysis proved the efficiency of the detection system. This simple, effective, and consistent method for glucose measurement shows that CMOS image sensors are efficient devices for monitoring glucose in point-of-care applications.
Collapse
Affiliation(s)
- Jasmine Pramila Devadhasan
- Department of Bionanotechnology, Gachon University, San 65, Bokjeong-Dong, Sujeong-Gu, Seongnam-Si, Gyeonggi-Do 461-701, Republic of Korea.
| | | | | |
Collapse
|
4
|
Christiansen M, Bailey T, Watkins E, Liljenquist D, Price D, Nakamura K, Boock R, Peyser T. A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Ther 2013; 15:881-8. [PMID: 23777402 PMCID: PMC3781114 DOI: 10.1089/dia.2013.0077] [Citation(s) in RCA: 112] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND Use of continuous glucose monitoring (CGM) systems can improve glycemic control, but widespread adoption of CGM utilization has been limited, in part because of real and perceived problems with accuracy and reliability. This study compared accuracy and performance metrics for a new-generation CGM system with those of a previous-generation device. SUBJECTS AND METHODS Subjects were enrolled in a 7-day, open-label, multicenter pivotal study. Sensor readings were compared with venous YSI measurements (blood glucose analyzer from YSI Inc., Yellow Springs, OH) every 15 min (±5 min) during in-clinic visits. The aggregate and individual sensor accuracy and reliability of a new CGM system, the Dexcom(®) (San Diego, CA) G4™ PLATINUM (DG4P), were compared with those of the previous CGM system, the Dexcom SEVEN(®) PLUS (DSP). RESULTS Both study design and subject characteristics were similar. The aggregate mean absolute relative difference (MARD) for DG4P was 13% compared with 16% for DSP (P<0.0001), and 82% of DG4P readings were within ± 20 mg/dL (for YSI ≤ 80 mg/dL) or 20% of YSI values (for YSI >80 mg/dL) compared with 76% for DSP (P<0.001). Ninety percent of the DG4P sensors had an individual MARD ≤ 20% compared with only 76% of DSP sensors (P=0.015). Half of DG4P sensors had a MARD less than 12.5% compared with 14% for the DSP sensors (P=0.028). The mean absolute difference for biochemical hypoglycemia (YSI <70 mg/dL) for DG4P was 11 mg/dL compared with 16 mg/dL for DSP (P<0.001). CONCLUSIONS The performance of DG4P was significantly improved compared with that of DSP, which may increase routine clinical use of CGM and improve patient outcomes.
Collapse
|
5
|
Heo YJ, Takeuchi S. Towards smart tattoos: implantable biosensors for continuous glucose monitoring. Adv Healthc Mater 2013. [PMID: 23184404 DOI: 10.1002/adhm.201200167] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Diabetes can strike at any age, from childhood to adulthood, and lasts a lifetime. Thus, it is important to find ways to increase the quality of life for diabetic patients through intensive, continuous care of blood glucose concentrations. Glucose biosensors that are implanted under the skin are promising for continuous glucose monitoring because they can constantly read blood glucose concentrations and signal a warning in case of hypo- or hyperglycemia. The demand for subcutaneous glucose biosensors has led to the development of many glucose-sensing principles and sensor designs. This Review covers the effort to develop subcutaneous glucose biosensors, including the glucose-sensing principles, and discusses their current status for in vivo monitoring. In addition, the Review examines the future prospects for intensive diabetes care.
Collapse
Affiliation(s)
- Yun Jung Heo
- Institute of Industrial Science, The University of Tokyo, Meguro-ku, Tokyo, Japan
| | | |
Collapse
|
6
|
Enzymatic Glucose Biosensors Based on Nanomaterials. ADVANCES IN BIOCHEMICAL ENGINEERING/BIOTECHNOLOGY 2013; 140:203-19. [DOI: 10.1007/10_2013_230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Huang X, Leduc C, Ravussin Y, Li S, Davis E, Song B, Wang Q, Accili D, Leibel R, Lin Q. Continuous monitoring of glucose in subcutaneous tissue using microfabricated differential affinity sensors. J Diabetes Sci Technol 2012; 6:1436-44. [PMID: 23294791 PMCID: PMC3570886 DOI: 10.1177/193229681200600625] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE We describe miniaturized differential glucose sensors based on affinity binding between glucose and a synthetic polymer. The sensors possess excellent resistance to environmental disturbances and can potentially allow wireless measurements of glucose concentrations within interstitial fluid in subcutaneous tissue for long-term, stable continuous glucose monitoring (CGM). METHODS The sensors are constructed using microelectromechanical systems (MEMS) technology and exploit poly(N-hydroxy-ethyl acrylamide-ran-3-acrylamidophenylboronic acid) (PHEAA-ran-PAAPBA), a glucose-binding polymer with excellent specificity, reversibility, and stability. Two sensing approaches have been investigated, which respectively, use a pair of magnetically actuated diaphragms and perforated electrodes to differentially measure the glucose-binding-induced changes in the viscosity and permittivity of the PHEAA-ran-PAAPBA solution with respect to a reference, glucose-unresponsive polymer solution. RESULTS In vivo characterization of the MEMS affinity sensors were performed by controlling blood glucose concentrations of laboratory mice by exogenous glucose and insulin administration. The sensors experienced an 8-30 min initialization period after implantation and then closely tracked commercial capillary glucose meter readings with time lags ranging from 0-15 min during rapid glucose concentration changes. Clarke error grid plots obtained from sensor calibration suggest that, for the viscometric and dielectric sensors, respectively, approximately 95% (in the hyperglycemic range) and 84% (ranging from hypoglycemic to hyperglycemic glucose concentrations) of measurement points were clinically accurate, while 5% and 16% of the points were clinically acceptable. CONCLUSIONS The miniaturized MEMS sensors explore differential measurements of affinity glucose recognition. In vivo testing demonstrated excellent accuracy and stability, suggesting that the devices hold the potential to enable long-term and reliable CGM in clinical applications.
Collapse
Affiliation(s)
- Xian Huang
- Department of Mechanical Engineering, Columbia University, New York, NY 10027, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ju YM, Yu B, West L, Moussy Y, Moussy F. A novel porous collagen scaffold around an implantable biosensor for improving biocompatibility. II. Long-term in vitro/in vivo sensitivity characteristics of sensors with NDGA- or GA-crosslinked collagen scaffolds. J Biomed Mater Res A 2010; 92:650-8. [PMID: 19235209 DOI: 10.1002/jbm.a.32400] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We have developed a new 3D porous and biostable collagen scaffold for implantable glucose sensors. The scaffolds were fabricated around the sensors and crosslinked using nordihydroguaiaretic acid (NDGA) or glutaraldehyde (GA) to enhance physical and biological stability. The effect of the scaffolds on sensor function and biocompatibility was examined during long-term (>or=28 days) in vitro and in vivo experiments and compared with control bare sensors. To evaluate the effect of the sensor length on micromotion and sensor function, we also fabricated short and long sensors. 3D porous scaffold application around glucose sensors did not significantly affect the long-term in vitro sensitivity of the sensors. The scaffolds, crosslinked by either NDGA or GA, remained stable around the sensors during the 4 week in vitro study. In the long-term in vivo study, the sensitivity of the short sensors was higher than the sensitivity of long sensors presumably because of less micromotion in the subcutis of the rats. The sensors with NDGA-crosslinked scaffolds had a higher sensitivity than the sensors with GA-crosslinked scaffolds. Histological examination showed that NDGA-crosslinked scaffolds retained their physical structure with reduced inflammation when compared with the GA-crosslinked scaffolds. Therefore, the application of NDGA-crosslinked collagen scaffolds might be a good method for enhancing the function and lifetime of implantable biosensors by minimizing the in vivo foreign body response.
Collapse
Affiliation(s)
- Young Min Ju
- Biomedical Engineering Program, University of South Florida, 4202 E. Fowler Avenue, ENB 118, Tampa, Florida 33620-5350, USA
| | | | | | | | | |
Collapse
|
9
|
Zisser HC, Bailey TS, Schwartz S, Ratner RE, Wise J. Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. J Diabetes Sci Technol 2009; 3:1146-54. [PMID: 20144429 PMCID: PMC2769895 DOI: 10.1177/193229680900300519] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND The purpose of this study was to compare the accuracy of measurements obtained from the DexCom SEVEN system with Yellow Springs Instrument (YSI) laboratory measurements of venous blood glucose. METHODS Seventy-two subjects with insulin-requiring diabetes, aged 18-71, were enrolled in a multicenter, prospective single-arm study. All participants wore the SEVEN continuous glucose monitoring (CGM) system for one, 7-day wear period. Calibration with capillary finger stick measurements was performed 2 hours after sensor insertion and once every 12 hours thereafter. A subset of subjects (28) wore two systems simultaneously to assess precision. All subjects participated in one, 10-hour in-clinic session on day 1, 4, or 7 of the study to compare CGM measurements against a laboratory method (YSI analyzer) using venous measurements taken once every 20 minutes. Carbohydrate consumption and insulin dosing were adjusted in order to obtain a broad range of glucose values. RESULTS Comparison of CGM measurements with the laboratory reference method (n = 2318) gave mean and median absolute relative differences (ARDs) of 16.7 and 13.2%, respectively. The percentage was 70.4% in the clinically accurate Clarke error grid A zone and 27.5% in the benign error B zone. Performance of the SEVEN system was consistent over time with mean and median ARD lowest on day 7 as compared to YSI (13.3 and 10.2%, respectively). Average sensor time lag was 5 minutes. CONCLUSIONS Measurements of the DexCom SEVEN system were found to be consistent and accurate compared with venous measurements made using a laboratory reference method over 7 days of wear.
Collapse
Affiliation(s)
- Howard C Zisser
- Sansum Diabetes Research Institute and University of California at Santa Barbara, Santa Barbara, California 93105, USA.
| | | | | | | | | |
Collapse
|
10
|
Wang Y, Percival MW, Dassau E, Zisser HC, Jovanovič L, Doyle FJ. A novel adaptive basal therapy based on the value and rate of change of blood glucose. J Diabetes Sci Technol 2009; 3:1099-108. [PMID: 20144423 PMCID: PMC2769919 DOI: 10.1177/193229680900300513] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Modern insulin pump therapy for type 1 diabetes mellitus offers the freedom to program several basal profiles that may accommodate diurnal ariability in insulin sensitivity and activity level. However, these basal profiles do not change even if a pending hypoglycemic or hyperglycemic event is foreseen. New insulin pumps could receive a direct feed of glucose values from a continuous glucose monitoring (CGM) system and could enable dynamic basal adaptation to improve glycemic control. METHOD The proposed method is a two-step procedure. After the design of an initial basal profile, an adaptation of the basal rate is suggested as a gain multiplier based on the current CGM glucose value and its rate of change (ROC). Taking the glucose value and its ROC as axes, a two-dimensional plane is divided into a nine-zone mosaic, where each zone is given a predefined basal multiplier; for example, a basal multiplier of zero indicates a recommendation to shut off the pump. RESULTS The proposed therapy was evaluated on 20 in silico subjects (ten adults and ten adolescents) in the Food and Drug Administration-approved UVa/Padova simulator. Compared with conventional basal therapy, the proposed basal adjustment improved the percentage of glucose levels that stayed in the range of 60-180 mg/dl for all 20 subjects. In addition, the adaptive basal therapy reduced the average blood glucose index values. CONCLUSIONS The proposed therapy provides the flexibility to account for insulin sensitivity variations that may result from stress and/or physical activities. Because of its simplicity, the proposed method could be embedded in a chip in a future artificial pancreatic beta cell or used in a "smart" insulin pump.
Collapse
Affiliation(s)
- Youqing Wang
- Department of Chemical Engineering, University of California, Santa Barbara, California
- Biomolecular Science and Engineering Program, University of California, Santa Barbara, California
- Sansum Diabetes Research Institute, Santa Barbara, California
| | - Matthew W. Percival
- Department of Chemical Engineering, University of California, Santa Barbara, California
- Sansum Diabetes Research Institute, Santa Barbara, California
| | - Eyal Dassau
- Department of Chemical Engineering, University of California, Santa Barbara, California
- Biomolecular Science and Engineering Program, University of California, Santa Barbara, California
- Sansum Diabetes Research Institute, Santa Barbara, California
| | - Howard C. Zisser
- Department of Chemical Engineering, University of California, Santa Barbara, California
- Sansum Diabetes Research Institute, Santa Barbara, California
| | - Lois Jovanovič
- Department of Chemical Engineering, University of California, Santa Barbara, California
- Biomolecular Science and Engineering Program, University of California, Santa Barbara, California
- Sansum Diabetes Research Institute, Santa Barbara, California
| | - Francis J. Doyle
- Department of Chemical Engineering, University of California, Santa Barbara, California
- Biomolecular Science and Engineering Program, University of California, Santa Barbara, California
- Sansum Diabetes Research Institute, Santa Barbara, California
| |
Collapse
|
11
|
Wang Y, Dassau E, Doyle FJ. Closed-loop control of artificial pancreatic Beta -cell in type 1 diabetes mellitus using model predictive iterative learning control. IEEE Trans Biomed Eng 2009; 57:211-9. [PMID: 19527957 DOI: 10.1109/tbme.2009.2024409] [Citation(s) in RCA: 121] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A novel combination of iterative learning control (ILC) and model predictive control (MPC), referred to here as model predictive iterative learning control (MPILC), is proposed for glycemic control in type 1 diabetes mellitus. MPILC exploits two key factors: frequent glucose readings made possible by continuous glucose monitoring technology; and the repetitive nature of glucose-meal-insulin dynamics with a 24-h cycle. The proposed algorithm can learn from an individual's lifestyle, allowing the control performance to be improved from day to day. After less than 10 days, the blood glucose concentrations can be kept within a range of 90-170 mg/dL. Generally, control performance under MPILC is better than that under MPC. The proposed methodology is robust to random variations in meal timings within +/-60 min or meal amounts within +/-75% of the nominal value, which validates MPILC's superior robustness compared to run-to-run control. Moreover, to further improve the algorithm's robustness, an automatic scheme for setpoint update that ensures safe convergence is proposed. Furthermore, the proposed method does not require user intervention; hence, the algorithm should be of particular interest for glycemic control in children and adolescents.
Collapse
Affiliation(s)
- Youqing Wang
- Department of Chemical Engineering and Biomolecular Science and Engineering Program, University of California, Santa Barbara, CA 93106, USA.
| | | | | |
Collapse
|
12
|
Dungel P, Long N, Yu B, Moussy Y, Moussy F. Study of the effects of tissue reactions on the function of implanted glucose sensors. J Biomed Mater Res A 2008; 85:699-706. [PMID: 17876777 DOI: 10.1002/jbm.a.31593] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The relationship between tissue reactions to a subcutaneously implanted glucose sensor and the function of the sensor was evaluated over a period of 4-weeks using tubular, porous polyvinyl alcohol (PVA) sponges implanted subcutaneously in rats. The PVA sponges were used as scaffolds in which the foreign body response could develop. Coil-type glucose sensors were then placed in the center of the PVA sponges and tested on day 3, and weekly thereafter. In the first approach, the sensors were placed in the sponges still implanted in the rats and tested. In vivo glucose sensor sensitivity peaked at day 7 and steadily decreased until day 35. In the second approach, the sensors were placed in the explanted sponges and then tested. This test showed no sensor function after day 7, indicating that functional blood vessels are critical in maintaining any function whatsoever. In both cases the sensors themselves were never implanted to eliminate any potential in vivo degradation of the sensors that could have affected the outcome of this study. Sensors were then tested in absence of sponges and found to be working properly with no change from preimplantation sensitivity. Once sensor testing was concluded, the PVA sponge/tissue samples were prepared for quantitative histological analysis. It was determined that the increase in collagen deposition within the sponge correlated with the decrease in sensor sensitivity. It was also observed that natural angiogenesis (peak at day 14) did not overcome the barrier to glucose diffusion created by the fibrous capsule.
Collapse
Affiliation(s)
- Paul Dungel
- Department of Chemical Engineering, The University of South Florida, 4202 East Fowler Avenue, ENB 118, Tampa, Florida 33620-5350, USA
| | | | | | | | | |
Collapse
|
13
|
Taub MB, Peyser TA, Erik Rosenquist J. Numerical simulation of the effect of rate of change of glucose on measurement error of continuous glucose monitors. J Diabetes Sci Technol 2007; 1:685-94. [PMID: 19885136 PMCID: PMC2769653 DOI: 10.1177/193229680700100512] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND A 5-day in-patient study designed to assess the accuracy of the FreeStyle Navigator Continuous Glucose Monitoring System revealed that the level of accuracy of the continuous sensor measurements was dependent on the rate of glucose change. When the absolute rate of change was less than 1 mg*dl(-1)*min(-1) (75% of the time), the median absolute relative difference (ARD) was 8.5%, with 85% of all points falling within the A zone of the Clarke error grid. When the absolute rate of change was greater than 2 mg*dl(-1)*min(-1) (8% of the time), the median ARD was 17.5%, with 59% of all points falling within the Clarke A zone. METHOD Numerical simulations were performed to investigate effects of the rate of change of glucose on sensor measurement error. This approach enabled physiologically relevant distributions of glucose values to be reordered to explore the effect of different glucose rate-of-change distributions on apparent sensor accuracy. RESULTS The physiological lag between blood and interstitial fluid glucose levels is sufficient to account for the observed difference in sensor accuracy between periods of stable glucose and periods of rapidly changing glucose. CONCLUSIONS The role of physiological lag on the apparent decrease in sensor accuracy at high glucose rates of change has implications for clinical study design, regulatory review of continuous glucose sensors, and development of performance standards for this new technology. This work demonstrates the difficulty in comparing accuracy measures between different clinical studies and highlights the need for studies to include both relevant glucose distributions and relevant glucose rate-of-change distributions.
Collapse
Affiliation(s)
- Marc B Taub
- Abbott Diabetes Care, Alameda, California. 94502, USA.
| | | | | |
Collapse
|
14
|
Beck J, Angus R, Madsen B, Britt D, Vernon B, Nguyen KT. Islet encapsulation: strategies to enhance islet cell functions. ACTA ACUST UNITED AC 2007; 13:589-99. [PMID: 17518605 DOI: 10.1089/ten.2006.0183] [Citation(s) in RCA: 146] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Diabetes is one of the most prevalent, costly, and debilitating diseases in the world. Although traditional insulin therapy has alleviated the short-term effects, long-term complications are ubiquitous and harmful. For these reasons, alternative treatment options are being developed. This review investigates one appealing area: cell replacement using encapsulated islets. Encapsulation materials, encapsulation methods, and cell sources are presented and discussed. In addition, the major factors that currently limit cell viability and functionality are reviewed, and strategies to overcome these limitations are examined. This review is designed to introduce the reader to cell replacement therapy and cell and tissue encapsulation, especially as it applies to diabetes.
Collapse
Affiliation(s)
- Jonathan Beck
- Department of Biological and Irrigation Engineering, Utah State University, Logan, Utah, USA
| | | | | | | | | | | |
Collapse
|
15
|
Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGarraugh GV. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 2007; 30:1125-30. [PMID: 17337488 DOI: 10.2337/dc06-1602] [Citation(s) in RCA: 164] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE The purpose of this study was to compare the accuracy of measurements of glucose in interstitial fluid made with the FreeStyle Navigator Continuous Glucose Monitoring System with Yellow Springs Instrument laboratory reference measurements of venous blood glucose. RESEARCH DESIGN AND METHODS Fifty-eight subjects with type 1 diabetes, aged 18-64 years, were enrolled in a multicenter, prospective, single-arm study. Each subject wore two sensors simultaneously, which were calibrated with capillary fingerstick measurements at 10, 12, 24, and 72 h after insertion. Measurements from the FreeStyle Navigator system were collected at 1-min intervals and compared with venous measurements taken once every 15 min for 50 h over the 5-day period of sensor wear in an in-patient clinical research center. Periods of high rates of change of glucose were induced by insulin and glucose challenges. RESULTS Comparison of the FreeStyle Navigator measurements with the laboratory reference method (n = 20,362) gave mean and median absolute relative differences (ARDs) of 12.8 and 9.3%, respectively. The percentage in the clinically accurate Clarke error grid A zone was 81.7% and that in the in the benign error B zone was 16.7%. During low rates of change (< +/-1 mg x dl(-1) x min(-1)), the percentage in the A zone was higher (84.9%) and the mean and median ARDs were lower (11.7 and 8.5%, respectively). CONCLUSIONS Measurements with the FreeStyle Navigator system were found to be consistent and accurate compared with venous measurements made using a laboratory reference method over 5 days of sensor wear (82.5% in the A zone on day 1 and 80.9% on day 5).
Collapse
Affiliation(s)
- Richard L Weinstein
- Diablo Clinical Research, 2255 Ygnacio Valley Rd., Suite M, Walnut Creek, CA 94598, USA.
| | | | | | | | | | | |
Collapse
|
16
|
Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006; 55:3344-50. [PMID: 17130478 DOI: 10.2337/db06-0419] [Citation(s) in RCA: 273] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
An automated closed-loop insulin delivery system based on subcutaneous glucose sensing and subcutaneous insulin delivery was evaluated in 10 subjects with type 1 diabetes (2 men, 8 women, mean [+/-SD] age 43.4 +/- 11.4 years, duration of diabetes 18.2 +/- 13.5 years). Closed-loop control was assessed over approximately 30 h and compared with open-loop control assessed over 3 days. Closed-loop insulin delivery was calculated using a model of the beta-cell's multiphasic insulin response to glucose. Plasma glucose was 160 +/- 66 mg/dl at the start of closed loop and was thereafter reduced to 71 +/- 19 by 1:00 p.m. (preprandial lunch). Fasting glucose the subsequent morning on closed loop was not different from target (124 +/- 25 vs. 120 mg/dl, respectively; P > 0.05). Mean glucose levels were not different between the open and closed loop (133 +/- 63 vs. 133 +/- 52 mg/dl, respectively; P > 0.65). However, glucose was within the range 70-180 mg/dl 75% of the time under closed loop versus 63% for open loop. Incidence of biochemical hypoglycemia (blood glucose <60 mg/dl) was similar under the two treatments. There were no episodes of severe hypoglycemia. The data provide proof of concept that glycemic control can be achieved by a completely automated external closed-loop insulin delivery system.
Collapse
Affiliation(s)
- Garry M Steil
- Medtronic MiniMed, 18000 Devonshire St., Northridge, CA 91325, USA.
| | | | | | | | | |
Collapse
|
17
|
Abstract
BACKGROUND The last two decades have witnessed unprecedented technological progress in the development of continuous glucose sensors, resulting in the first generation of commercial glucose monitors. This has fuelled the development of prototypes of a closed-loop system based on the combination of a continuous monitor, a control algorithm, and an insulin pump. METHOD A review of electromechanical closed-loop approaches is presented. This is followed by a review of existing prototypes and associated glucose sensors. A literature review was undertaken from 1960 to 2004. RESULTS Two main approaches exist. The extracorporeal s.c.-s.c. approach employs subcutaneous glucose monitoring and subcutaneous insulin delivery. The implantable i.v.-i.p. approach adopts intravenous sampling and intraperitoneal insulin delivery. Feasibility of both solutions has been demonstrated in small-scale laboratory studies using either the classical proportional-integral-derivative controller or a model predictive controller. Performance in the home setting has yet to be demonstrated. CONCLUSIONS The glucose monitor remains the main limiting factor in the development of a commercially viable closed-loop system, as presently available monitors fail to demonstrate satisfactory characteristics in terms of reliability and/or accuracy. Regulatory issues are the second limiting factor. Closed-loop systems are likely to be used first by health-care professionals in controlled environments such as intensive care units.
Collapse
Affiliation(s)
- R Hovorka
- Diabetes Modelling Group, Department of Paediatrics, University of Cambridge, Cambridge, UK.
| |
Collapse
|
18
|
Long N, Yu B, Moussy Y, Moussy F. Strategies for testing long-term transcutaneous amperometric glucose sensors. Diabetes Technol Ther 2005; 7:927-36. [PMID: 16386099 DOI: 10.1089/dia.2005.7.927] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVES Transcutaneous and embedded devices were developed for use in characterizing the in vivo performance of subcutaneously implanted glucose sensors. The devices were used as a portal for accessing electrochemical glucose sensors from the exterior. They were designed to prevent the sensors from being pulled out of the animals and the sensor leads from breaking. Development of the devices took into consideration rodent mobility, infection control, and animal welfare balanced with sensor durability, accessibility, and functionality. METHODS Our approach was developed over five animal protocols spanning a period of 6 months. A total of 68 sensors were implanted with 60 associated devices in 22 Sprague-Dawley outbred rats. RESULTS The average sensor lifetime was 11.2 +/- 3.1 days with a maximum of 56 days. All-cause sensor failure averaged one sensor per day. As implantation devices were modified, failure attributable to the device was decreased by 40%. The resulting devices showed good durability and allowed for easy sensor access and testing. CONCLUSIONS These data represent baseline sensor function against which future sensor improvements may be measured. The new devices and techniques described should be a valuable tool in the development of continuous glucose sensors.
Collapse
Affiliation(s)
- Nathan Long
- Department of Chemical Engineering, The University of South Florida, Tampa, Florida 33620-5350, USA
| | | | | | | |
Collapse
|
19
|
Steil GM, Rebrin K. Closed-loop insulin delivery – what lies between where we are and where we are going? Expert Opin Drug Deliv 2005; 2:353-62. [PMID: 16296759 DOI: 10.1517/17425247.2.2.353] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Closed-loop insulin delivery in individuals with diabetes can potentially lead to near-normal glucose profiles. To this end, existing subcutaneous glucose sensors and external insulin pumps can be linked with an insulin delivery algorithm to create a completely automated closed-loop system. This paper reviews current research into the development of such a system, with particular emphasis on creating a system emulating the physiological properties of the beta-cell. Issues related to using subcutaneous interstitial fluid for glucose sensing and insulin delivery are reviewed. Criteria for optimising the system are discussed using historical data. Existing strategies for open-loop pump therapy are presented with the objective of defining a path to advance from the existing physician/patient determined insulin therapy to a completely automated system.
Collapse
|